Studies tiny cell-released particles in obesity and heart and metabolic disease
Looks at fat, liver and heart signals in adults having weight loss surgery.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- EVOC - EVs in Obesity and Cardiometabolic Disease
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 2 Feb 2019
- Expected to end
- 1 Jul 2028
- Type of study
- Observational
- Record updated
- 17 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who are having weight loss (bariatric) surgery. Fat tissue and blood samples will be collected.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Obesity with a BMI of 30 kg/m2 or more. For 20 patients, pre-diabetes or diabetes is also needed.
- Biomarker or test result
- For the 20 patients with pre-diabetes or diabetes: HgbA1c above 5.7 or fasting blood glucose above 100.
Main reasons for not taking part
- Pregnancy
- Earlier heart attack (myocardial infarction)
- Valvular heart disease
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age greater than or equal to 18 years of age
- Obese (BMI>/=30 kg/m2; for obesity/bariatric surgery group)
- For 20 patients, additional criteria will be presence of pre-diabetes or diabetes (HgbA1c > 5.7 or Fasting blood glucose > 100)
Who cannot take part
- Prior clinical history of myocardial infarction or valvular heart disease
- Pregnancy (as adjudicated by patient history)
Where in United States
- Massachusetts General HospitalBoston, United StatesContact: Clinical Research CoordinatorTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to research the impact of molecular signals from the heart, liver and fat tissue on cardiovascular disease risk, and the presentation of Type II Diabetes and diseases that affect the heart, blood vessels and metabolism (Cardiometabolic Disease). Specifically, the focus is on the content and function of Extracellular Vesicles (EVs), small sacs released from a cell's surface that contain important molecular cargo. The main questions it aims to answer are:
Read full original descriptionShow less
1. What molecular cargo do adipose-tissue EVs carry? 2. How do these cargo impact cardiac and hepatic function? 3. Are changes in EV content related to cardiac function and adiposity with weight loss?
Tissue samples from fat tissue and blood samples will be collected from patients receiving bariatric weight loss surgery.
The group in the trial
- Bariatric Surgery
Patients undergoing bariatric surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Extracellular Vesicle Signaling in Obesity and Cardiometabolic Disease (EVOC)
- Plain-language title
- Studies tiny cell-released particles in obesity and heart and metabolic diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 June 2026